ZURAMPIC (lesinurad), uricosuric

Low clinical benefit, in combination with an xanthine oxidase inhibitor (IXO), in gout-related hyperuricaemia under conditions of IXO failure, though no clinical advantage in the therapeutic strategy.

• ZURAMPIC has been granted marketing authorisation, in combination with an IXO, in adults, for the adjuvant treatment of hyperuricaemia in patients suffering from gout (with or without tophus) who failed to reach the target uric acid levels with an appropriate dose of IXO administered alone.

• When used in combination with an IXO (allopurinol or febuxostat), it has demonstrated its efficacy versus placebo in terms of the proportion of patients reaching target uricaemia levels after 6 months of treatment.

• It has not demonstrated its efficacy in terms of reduction of goutflares.